Increased vaccine efficacy against tuberculosis with a recombinant BCG overexpressing the STING agonist cyclic di-AMP.

ABSTRACT: Tuberculosis (TB) remains the leading cause of death due to infection globally. Bacillus Calmette Guérin (BCG), a live attenuated bacterial strain, is the only available TB vaccine, but it has poor efficacy in preventing pulmonary TB in adults. There are advantages associated with the BCG platform however, including a remarkable safely profile, billions of administered doses and a public health ecosystem associated with its production, administration and care. A recombinant/modified BCG (rBCG/modBCG) anti-TB vaccine candidate would be able to leverage these advantages while improving on efficacy. BCG-STING is a recombinant BCG strain which overexpresses the mycobacterial diadenylate cyclase disA gene leading to the release of ∼15-fold greater levels of the endogenous small molecule

SUBMITTER: Singh DK 

PROVIDER: S-EPMC12338612 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature